Literature DB >> 7927237

Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites.

P Angeli1, W Jiménez, V Arroyo, H S Mackenzie, P L Zhang, J Clària, F Rivera, B M Brenner, J Rodés.   

Abstract

The aim of this study was to assess the effect of HS-142-1, a recently discovered specific antagonist of endogenous natriuretic peptides, on systemic hemodynamics, renal function, and the renin-aldosterone system in rats with cirrhosis and ascites. The study consisted of three protocols, each including 10 conscious control rats and 10 conscious rats with carbon-tetrachloride-induced cirrhosis with ascites. In protocol 1, HS-142-1 administration (by intravenous bolus of 20 mg.kg-1.body weight in all protocols) was not associated with significant changes in mean arterial pressure, heart rate, cardiac output or total peripheral resistance in the two groups of animals. In protocol 2, HS-142-1 induced a significant reduction in glomerular filtration rate (from 4.2 +/- 0.5 to 2.6 +/- 0.3 ml/min, p < 0.025) in control animals. A decrease in renal plasma flow and an increase in renal vascular resistance also occurred, but these changes were not statistically significant. In cirrhotic rats, HS-142-1 resulted in a significant decrease in renal plasma flow (from 10.9 +/- 0.7 to 4.3 +/- 0.6 ml/min, p < 0.001) and a significant increase in renal vascular resistance (from 6.0 +/- 0.6 to 16.3 +/- 2.7 mm Hg.min.ml-1, p < 0.025). Glomerular filtration rate decreased more in cirrhotic rats with ascites than in control rats (from 3.8 +/- 0.3 to 1.3 +/- 0.2 ml/min, p < 0.001). Changes in urine flow rate and urinary sodium excretion rate paralleled those of glomerular filtration rate in both groups of animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927237     DOI: 10.1002/hep.1840200425

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  4 in total

Review 1.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

2.  Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure.

Authors:  V Gülberg; S Møller; J H Henriksen; A L Gerbes
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

3.  Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites.

Authors:  P Y Martin; M Ohara; P Gines; D L Xu; J St John; M Niederberger; R W Schrier
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

Review 4.  Optimal management of hepatorenal syndrome in patients with cirrhosis.

Authors:  Paolo Angeli; Filippo Morando
Journal:  Hepat Med       Date:  2010-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.